Assigned ID Abstract Title Presenting Author First Name Presenting
Total Page:16
File Type:pdf, Size:1020Kb
Assigned ID Abstract Title Presenting Author First Presenting Author Accepted Presentation Category Sub-category Name Last Name Preference LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with resected pancreatic cancer: Updated 5-year overall survival Margaret Tempero Oral Presentation Clinical Pancreatic Cancer Early and Locally Advanced Disease LBA-2 Selected Abstract Oral Presentation Clinical Hepatocellular Carcinoma Early and Locally Advanced Disease Metastatic Disease LBA-3 Integrated analysis of cell free DNA BRAF mutant allele fraction and whole exome sequencing in BRAFV600E metastatic colorectal cancer treated with BRAF - Elena Elez Oral Presentation Basic Colon Cancer Metastatic Disease antiEFGR +/- MEK inhibitors. LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or Yelena Yuriy Janjigian Oral Presentation Clinical Colon Cancer Biomarkers and Translational Research gastroesophageal junction (G/GEJ) cancer LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer Zev Wainberg Oral Presentation Clinical Esophageal Cancer Metastatic Disease O-1 Results from a global Phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma Ghassan Abou-Alfa Oral Presentation Clinical Hepatocellular Carcinoma Others: PD-1 Inhibitor Monotherapy O-2 Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors Jonathan Strosberg Oral Presentation Clinical Bilary Tract Cancer Biomarkers and Translational Research O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies Mohamed Salem Oral Presentation Clinical Colon Cancer Biomarkers and Translational Research O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications Corinna Slawinski Oral Presentation Clinical Colon Cancer Screening/Prevention/Epidemiology for treating obese patients: The OCTOPUS consortium O-5 Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection Melissa Lumish Oral Presentation Others ( Including GIST and Anal Cancer ) Metastatic Disease O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus Naoki Takahashi Oral Presentation Clinical Colon Cancer Biomarkers and Translational Research trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study Manish A. Shah Oral Presentation Clinical Colon Cancer Metastatic Disease Others: Phase 3 trial O-8 Selected Abstract Oral Presentation Clinical Colon Cancer Metastatic Disease O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker Michel Ducreux Oral Presentation Clinical Colon Cancer Metastatic Disease findings from Cohort 1 of the MODUL trial O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic Eric Van Cutsem Oral Presentation Clinical Colon Cancer Metastatic Disease colorectal cancer O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study Hiromichi Shirasu Oral Presentation Clinical Colon Cancer Biomarkers and Translational Research GALAXY in CIRCULATE-Japan Surgery O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study Lisa Salvatore Oral Presentation Clinical Rectal Cancer Early and Locally Advanced Disease O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08) Yu Sunakawa Oral Presentation Clinical Gastric Cancer Biomarkers and Translational Research O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2- Kohei Shitara Oral Presentation Clinical Gastric Cancer Biomarkers and Translational Research positive or -low advanced gastric or gastroesophageal junction adenocarcinoma SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey Gerald Prager Short Oral Presentation Clinical Colon Cancer Others: Practice Patterns SO-2 Pancreatic cancer in HIV versus non-HIV population: Analysis of demographics, outcomes and healthcare utilization from a national sample Syed Ali Amir Sherazi Short Oral Presentation Clinical Pancreatic Cancer Screening/Prevention/Epidemiology SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe Julien Taieb Short Oral Presentation Clinical Pancreatic Cancer Metastatic Disease SO-4 Progression-free survival in patients With cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy Ghassan Abou-Alfa Short Oral Presentation Clinical Bilary Tract Cancer Others: Post-hoc analysis response SO-5 Tumor inflammation and proliferative status as biomarkers in gastroesophageal adenocarcinoma Sarbajit Mukherjee Short Oral Presentation Clinical Gastric Cancer Biomarkers and Translational Research SO-6 Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial Maximilian Kloft Short Oral Presentation Clinical Esophageal Cancer Biomarkers and Translational Research Pathology SO-7 The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database Lei Deng Short Oral Presentation Clinical Gastric Cancer Early and Locally Advanced Disease Others: Chemotherapy SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results Michele Maio Short Oral Presentation Others ( Including GIST and Anal Cancer ) Biomarkers and Translational Research from the KEYNOTE-158 study SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study Thierry André Short Oral Presentation Others ( Including GIST and Anal Cancer ) Others: immuno-oncology/immunotherapy SO-10 An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced Minkyu Jung Short Oral Presentation Clinical Gastric Cancer Metastatic Disease gastric cancer having alterations in PI3K/Akt pathway SO-11 KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – Scott Kopetz Short Oral Presentation Clinical Colon Cancer Biomarkers and Translational Research preliminary results from a Phase 1b study Metastatic Disease SO-12 Updated safety, efficacy, and PK results from an open-label, multicenter, phase I/II study of avapritinib in Chinese patients with unresectable or metastatic Jian Li Short Oral Presentation Others ( Including GIST and Anal Cancer ) Others: phase 1/2 clinical trials gastrointestinal stromal tumors SO-13 KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients Emerik Osterlund Short Oral Presentation Clinical Colon Cancer Biomarkers and Translational Research Metastatic Disease SO-14 The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study Yuki Matsubara Short Oral Presentation Clinical Colon Cancer Metastatic Disease Assigned ID Abstract Title Presenting Author First Presenting Author Accepted Presentation Category Sub-category Name Last Name Preference SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study Gabor Liposits Short Oral Presentation Clinical Colon Cancer Metastatic Disease SO-16 Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study Pia Osterlund Short Oral Presentation Clinical Colon Cancer Metastatic Disease NCT01531595) SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced Per Pfeiffer Short Oral Presentation Clinical Colon Cancer Early and Locally Advanced Disease peripheral neuropathy Screening/Prevention/Epidemiology SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, Julien Taieb Short Oral Presentation Clinical Colon Cancer